featured
Actionability of HER2-Amplified CTCs in HER2-Negative Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Breast Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Actionability of HER2-Amplified Circulating Tumor Cells in HER2-Negative Metastatic Breast Cancer: The CirCe T-DM1 Trial
Breast Cancer Res 2019 Nov 14;21(1)121, W Jacot, P Cottu, F Berger, C Dubot, L Venat-Bouvet, A Lortholary, H Bourgeois, M Bollet, V Servent, E Luporsi, M Espié, S Guiu, V D'Hondt, V Dieras, MP Sablin, E Brain, S Neffati, JY Pierga, FC BidardFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.